Literature DB >> 17167777

Activation of the S phase DNA damage checkpoint by mitomycin C.

Emil Mladenov1, Irina Tsaneva, Boyka Anachkova.   

Abstract

We have studied the rate of DNA synthesis, cell cycle distribution, formation of gamma-H2AX, and Rad51 nuclear foci and association of Rad51 with the nuclear matrix after treatment of HeLa cells with the interstrand crosslinking agent mitomycin C (MMC) in the presence of the kinase inhibitors caffeine and wortmannin. The results showed that MMC treatment arrested the cells in S-phase and induced the appearance of gamma-H2AX and Rad51 nuclear foci, accompanied with a sequestering of Rad51 to the nuclear matrix. These effects were abrogated by caffeine, which inhibits the Ataxia-telangiectasia mutated (ATM) and ATM- and Rad3-related (ATR) kinases. However, wortmannin at a concentration that inhibits ATM, but not ATR did not affect cell cycle progression, damage-induced phosphorylation of H2AX and Rad51 foci formation, and association with the nuclear matrix, suggesting that the S-phase arrest induced by MMC is ATR-dependent. These findings were confirmed by experiments with ATR-deficient and AT cells. They indicate that the DNA damage ATR-dependent S-phase checkpoint pathway may regulate the spatiotemporal organization of the process of repair of interstrand crosslinks. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17167777     DOI: 10.1002/jcp.20957

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  16 in total

1.  DNA Damage Does Not Cause BrdU Labeling of Mouse or Human β-Cells.

Authors:  Rohit B Sharma; Christine Darko; Xiaoying Zheng; Brian Gablaski; Laura C Alonso
Journal:  Diabetes       Date:  2019-03-04       Impact factor: 9.461

2.  Distinct cellular phenotype linked to defective DNA interstrand crosslink repair and homologous recombination.

Authors:  Aleksandra M Gorniewska; Katarzyna Kluzek; Lidia Gackowska; Izabela Kubiszewska; Malgorzata Z Zdzienicka; Aneta Bialkowska
Journal:  Mol Med Rep       Date:  2017-06-15       Impact factor: 2.952

3.  Mitomycin C: a promising agent for the treatment of canine corneal scarring.

Authors:  Rangan Gupta; Benjamin W Yarnall; Elizabeth A Giuliano; Jagat R Kanwar; Dylan G Buss; Rajiv R Mohan
Journal:  Vet Ophthalmol       Date:  2011-04-18       Impact factor: 1.644

4.  Snm1B/Apollo functions in the Fanconi anemia pathway in response to DNA interstrand crosslinks.

Authors:  Jennifer M Mason; JoAnn M Sekiguchi
Journal:  Hum Mol Genet       Date:  2011-04-08       Impact factor: 6.150

5.  Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cells.

Authors:  Jin-Jian Lu; Yu-Jun Cai; Jian Ding
Journal:  Mol Cell Biochem       Date:  2011-04-28       Impact factor: 3.396

6.  Characterization of DNA damage-dependent cell cycle checkpoints in a menin-deficient model.

Authors:  Molly C Kottemann; Allen E Bale
Journal:  DNA Repair (Amst)       Date:  2009-07-15

7.  Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway.

Authors:  B Cui; S P Johnson; N Bullock; F Ali-Osman; D D Bigner; H S Friedman
Journal:  Mol Pharmacol       Date:  2009-03-04       Impact factor: 4.436

8.  Cyclin E is stabilized in response to replication fork barriers leading to prolonged S phase arrest.

Authors:  Xiaoyan Lu; Jia Liu; Randy J Legerski
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

9.  Snm1B/Apollo mediates replication fork collapse and S Phase checkpoint activation in response to DNA interstrand cross-links.

Authors:  J-B Bae; S S Mukhopadhyay; L Liu; N Zhang; J Tan; S Akhter; X Liu; X Shen; L Li; R J Legerski
Journal:  Oncogene       Date:  2008-05-12       Impact factor: 9.867

10.  Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism.

Authors:  Mirth T Hoyt; Rahul Palchaudhuri; Paul J Hergenrother
Journal:  Invest New Drugs       Date:  2010-02-20       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.